Clinical Trials Browser

Triple Negative Breast Neoplasms

NCT07471815 2026-03-13

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

Phase 2 Active not recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05582499 2025-08-22

FASCINATE-N

Phase 2 Recruiting

716 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05475678 2025-01-23

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

Phase 2 Recruiting

369 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06731153 2024-12-12

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Phase 2 Not yet recruiting

40 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04613674 2024-03-27

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 3 Completed

441 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05999149 2024-02-21

BCTOP-T-N01

Phase 3 Recruiting

424 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05760378 2024-02-06

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Phase 3 Recruiting

223 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04395989 2023-12-22

FUTURE-SUPER

Phase 2 Unknown

139 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05928780 2023-07-03

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

Phase 1/2 Unknown

125 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05447702 2023-05-22

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 2 Recruiting

35 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04335006 2023-05-06

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Phase 3 Terminated

80 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05556200 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Phase 2 Unknown

58 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05670925 2023-02-28

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

Phase 2 Unknown

46 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Phase 1 Completed

32 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03805399 2022-08-10

FUTURE

Phase 1/2 Unknown

140 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05438706 2022-06-30

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Phase 2 Unknown

70 enrolled

Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04129996 2022-01-11

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

Phase 2 Unknown

46 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05088057 2021-10-21

Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

Phase 2 Unknown

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04907344 2021-05-28

Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 2/3 Unknown

420 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04676997 2020-12-21

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

Phase 2 Unknown

20 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04481763 2020-07-22

A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

Phase 1/2 Recruiting

20 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04213898 2019-12-30

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

Phase 1/2 Unknown

39 enrolled

Breast

Triple Negative Breast Neoplasms

Clinical Trials

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

FASCINATE-N

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

BCTOP-T-N01

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

FUTURE-SUPER

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

FUTURE

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer